title: In response.
authors.affiliation: Royal Adelaide Hospital, Adelaide, Australia Cabrini Medical Centre, Melbourne, Australia Royal North Shore Hospital, Sydney, Australia Metro Spinal Clinic, Melbourne, Australia Summit Analytical, Chicago, IL BioAssets Development Corporation, now a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd.
authors.forename: Brian J C
authors.initials: BJ
authors.lastname: Freeman
authors.forename: Guy L
authors.initials: GL
authors.lastname: Ludbrook
authors.forename: Stephen
authors.initials: S
authors.lastname: Hall
authors.forename: Michael
authors.initials: M
authors.lastname: Cousins
authors.forename: Bruce
authors.initials: B
authors.lastname: Mitchell
authors.forename: Mark
authors.initials: M
authors.lastname: Jaros
authors.forename: Michael
authors.initials: M
authors.lastname: Wyand
authors.forename: Michael
authors.initials: M
authors.lastname: Wyand
authors.forename: James R
authors.initials: JR
authors.lastname: Gorman
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007403:Intervertebral Disc / Q000187:drug effects*; D007405:Intervertebral Disc Displacement / Q000188:drug therapy*; D008159:Lumbar Vertebrae / Q000187:drug effects*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor